Influence of alpha-1 antitrypsin heterozygosity on treatment efficacy of HCV combination therapy (original) (raw)

European Journal of Gastroenterology & Hepatology, 2010

Abstract

BACKGROUND: The role of heterozygosity for alpha-1 antitrypsin (A1AT) alleles in patients with chronic hepatitis C virus (HCV) is unclear. There is limited evidence to suggest that there is an increased prevalence of heterozygous A1AT carriers in HCV, but it is unclear how this affects treatment success. AIM: To investigate the (i) prevalence of A1AT heterozygosity among two HCV cohorts

Thomas Berg hasn't uploaded this paper.

Let Thomas know you want this paper to be uploaded.

Ask for this paper to be uploaded.